Jacob Leander

7PUBLICATIONS
15CO-AUTHORS
Medical virologyToxicology (incl. clinical toxicology)Epidemiological modellingPharmacogenomicsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 06, 2026
A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease.

|Jul 06, 2026
Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthma.

|Jun 06, 2026
Modeling Peak Expiratory Flow in Patients With Asthma and Quantifying Treatment Effects Using a Mixed-Effects Hidden Markov Model.

|May 08, 2026
Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat.

|Jul 31, 2025
A machine learning approach to population pharmacokinetic modelling automation.

Sam Richardson, Itziar Irurzun Arana, Andrzej Nowojewski

|Nov 19, 2021
A stochastic mixed effects model to assess treatment effects and fluctuations in home-measured peak expiratory flow and the association with exacerbation risk in asthma.

Jacob Leander, Mats Jirstrand, Ulf G Eriksson

Pageof 2

Frequent Collaborators

2 joint publications

Mats Jirstrand

1 joint publications

Dinko Rekić

1 joint publications

Sam Richardson

1 joint publications

Itziar Irurzun Arana